HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sudlow, C. Articles by Hankey, G. Search for Related Content PubMed Articles by Sudlow, C. Articles by Hankey, G.

Antiplatelet Drugs in the Secondary Prevention of Stroke

¹ Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Edinburgh, UK;
² Royal Perth Hospital, Western Australia and Department of Medicine, University of Western Australia, E-mail: gjhankey{at}cyllene.uwa.edu.au

EXTRACT

INTRODUCTION

Stroke is a major cause of death and disability in developing and developed countries (Murray & Lopez 1996). Incidence rises steeply with age so that about three quarters of incident strokes occur in people over 65 years of age. In community-based studies among whites, around 80% of strokes are ischaemic, while 15% are due to primary intracerebral haemorrhage, and 5% to subarachnoid haemorrhage (Fig. 1). The proportion of haemorrhagic strokes in the mainly non-white populations of Asia and Africa may be somewhat higher, but ischaemic stroke is still the dominant problem (Sudlow & Warlow 1997).

The management of patients with acute ischaemic stroke aims to restore tissue perfusion, minimize cytotoxic brain damage and cerebral oedema, prevent complications of stroke, and prevent a recurrent stroke or other serious vascular event.

About 10% of patients with a first-ever acute ischaemic stroke die within 30 days of onset. Most of these early ...

[PDF of this article]